Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 6, 2020; 8(23): 5935-5943
Published online Dec 6, 2020. doi: 10.12998/wjcc.v8.i23.5935
Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
Rui-Bin Wang, Yu-Chen Li, Quan Zhou, Shu-Zhen Lv, Ke-Yu Yuan, Jiang-Ping Wu, Yan-Jie Zhao, Qing-Kun Song, Bin Zhu
Rui-Bin Wang, Department of Emergency, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Yu-Chen Li, Department of Cancer Research, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Quan Zhou, Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Shu-Zhen Lv, Ke-Yu Yuan, Department of Breast Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Jiang-Ping Wu, Yan-Jie Zhao, Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Qing-Kun Song, Department of Clinical Epidemiology and Evidence-based Medicine, Beijing Shijitan Hospital, Beijing 100038, China
Bin Zhu, Department of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Author contributions: Wang RB, Li YC and Zhou Q performed the majority of experiments and wrote the manuscript; Lv SZ, Yuan KY, Zhao YJ, and Song QK designed the study and corrected the manuscript; Wu JP and Wang RB contributed to data analysis; Song QK and Zhu B were responsible for designing and performing the study, manuscript reviewing and approval of the final version; Song QK and Zhu B contributed equally to this manuscript; all authors have read and approved the final manuscript.
Supported by Beijing Municipal Committee of Science and Technology, No. Z181100001718090 and Z19110006619041; Beijing Municipal Administration of Hospitals, No. PX2018029; Beijing Shijitan Hospital, Capital Medical University, No. 2017-KF01.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Beijing Shijitan Hospital, No. SJEC 2016-111.
Informed consent statement: All study participants or their legal guardian provided informed written consent regarding personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at songqingkun@aliyun.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Zhu, MD, Professor, Department of Surgical Oncology, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Haidian District, Beijing 100038, China. binbinzhu99@sohu.com
Received: July 18, 2020
Peer-review started: July 18, 2020
First decision: August 21, 2020
Revised: August 24, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: December 6, 2020
Core Tip

Core Tip: In this study, we showed that overexpression of CD155 in the breast cancer microenvironment had a significant association with a high level of programmed cell death ligand 1 expression, exhausted CD4+ helper T cells and unexhausted CD8+ cytotoxic T cells. CD155 expression was related to the inhibitory immune microenvironment and may be an immunotherapeutic target in breast cancer.